Ryan Livingston

Data from a recent trial of the OmniVu Lens System was presented at ASCRS 2026, featuring positive and sustained vision end points.

Luminopia, formerly cleared by the FDA for amblyopia in children, has begun its foray into IXT with positive data from a preliminary investigation.

The annual See Tomorrow survey conducted by the Contact Lens Institute and the United Opticians Association has highlighted a substantial portion of both opticians and patients interested in further education.

The ADVISE trial has demonstrated adalimumab’s superior management of intermediate uveitis, posterior uveitis, or panuveitis requiring immunosuppression.

A recent nonrandomized trial has demonstrated toric IOLs’ efficacy in providing long-term visual outcomes, reducing amblyopia compared to non-toric lenses.

A recent study highlights the efficacy of the FAi implant in patients with NIU-related macular edema, improving BCVA and reducing choroidal thickness.

According to recent data, patients initiating semaglutide had a substantially greater risk of developing NAION versus those starting SGLT2 inhibitors.